@article{MTMT:34763312,
	title = {PLGA‐Based Drug Delivery Systems: A Promising Carrier for Antidiabetic Drug Delivery},
	url = {https://m2.mtmt.hu/api/publication/34763312},
	author = {Sharmah, Bhaben and Borthakur, Amarjit and Manna, Prasenjit},
	doi = {10.1002/adtp.202300424},
	journal-iso = {ADV THER},
	journal = {ADVANCED THERAPEUTICS},
	unique-id = {34763312},
	abstract = {Poly(lactic‐ co ‐glycolic acid) (PLGA) nanoparticles have emerged as a versatile platform for drug delivery due to their biodegradability, biocompatibility, and tunable release kinetics. One of the primary applications of PLGA nanoparticles in diabetes management is the encapsulation and controlled release of insulin, overcoming the limitations of frequent injections. Such systems provide sustained and stable glycemic control, reducing the risk of hypoglycemia. Different types of PLGAs and their derivatives are used for preparing varieties of micro/nanocarriers to deliver insulin as well as diverse antidiabetic molecules, including glucagon‐like peptide‐1 (GLP‐1) and its analog (exendin‐4), crocetin, metformin hydrochloride, gliclazide, ferulic acid (FA), etc., to reduce hyperglycemia. Here the current state of research and development in PLGA‐based drug delivery systems for diabetes management are summarized. Various strategies employed to enhance the targeting specificity of PLGA nanoparticles in diabetes therapy are explored. The outcome will provide an insight into the drug delivery potential and efficiency of PLGA in managing hyperglycemia and that will be useful in designing novel therapeutic to improve better control of diabetes mellitus. As research in this field continues to progress, PLGA‐based systems hold great potential for revolutionizing the treatment paradigm for diabetes mellitus.},
	year = {2024},
	eissn = {2366-3987},
	orcid-numbers = {Manna, Prasenjit/0000-0003-1952-6531}
}

@article{MTMT:33784975,
	title = {Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes},
	url = {https://m2.mtmt.hu/api/publication/33784975},
	author = {Behzadifar, Shakila and Barras, Alexandre and Plaisance, Valérie and Pawlowski, Valérie and Szunerits, Sabine and Abderrahmani, Amar and Boukherroub, Rabah},
	doi = {10.3390/pharmaceutics15041215},
	journal-iso = {PHARMACEUTICS},
	journal = {PHARMACEUTICS},
	volume = {15},
	unique-id = {33784975},
	issn = {1999-4923},
	abstract = {Diabetes poses major economic, social, and public health challenges in all countries worldwide. Besides cardiovascular disease and microangiopathy, diabetes is a leading cause of foot ulcers and lower limb amputations. With the continued rise of diabetes prevalence, it is expected that the future burden of diabetes complications, early mortality, and disabilities will increase. The diabetes epidemic is partly caused by the current lack of clinical imaging diagnostic tools, the timely monitoring of insulin secretion and insulin-expressing cell mass (beta (β)-cells), and the lack of patients’ adherence to treatment, because some drugs are not tolerated or invasively administrated. In addition to this, there is a lack of efficient topical treatment capable of stopping the progression of disabilities, in particular for treating foot ulcers. In this context, polymer-based nanostructures garnered significant interest due to their tunable physicochemical characteristics, rich diversity, and biocompatibility. This review article emphasizes the last advances and discusses the prospects in the use of polymeric materials as nanocarriers for β-cell imaging and non-invasive drug delivery of insulin and antidiabetic drugs in the management of blood glucose and foot ulcers.},
	year = {2023},
	eissn = {1999-4923},
	pages = {1215},
	orcid-numbers = {Behzadifar, Shakila/0000-0003-2504-4600; Barras, Alexandre/0000-0003-2821-7079; Plaisance, Valérie/0000-0002-3403-9080; Pawlowski, Valérie/0000-0002-7708-7517; Szunerits, Sabine/0000-0002-1567-4943; Abderrahmani, Amar/0000-0003-0752-0343; Boukherroub, Rabah/0000-0002-9795-9888}
}

@article{MTMT:34387379,
	title = {A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres},
	url = {https://m2.mtmt.hu/api/publication/34387379},
	author = {Gao, Zejing and Wei, Yi and Ma, Guanghui},
	doi = {10.1039/D3TB02207B},
	journal-iso = {J MATER CHEM B},
	journal = {JOURNAL OF MATERIALS CHEMISTRY B},
	unique-id = {34387379},
	issn = {2050-750X},
	abstract = {This review provides key points in the development of glucagon-like peptide-1 receptor agonist-loaded microspheres from three aspects: preparation methods, strategies to maintain peptide bioactivity, and control the drug release from microspheres.},
	year = {2023},
	eissn = {2050-7518},
	orcid-numbers = {Wei, Yi/0000-0003-4175-5867; Ma, Guanghui/0000-0001-9154-5556}
}

@article{MTMT:34471844,
	title = {Kajian Rute Alternatif Pemberian Liraglutide dalam Penanganan Diabetes dan Obesitas},
	url = {https://m2.mtmt.hu/api/publication/34471844},
	author = {Immanuel, Handika},
	doi = {10.31942/jiffk.v20i2.9299},
	journal-iso = {Jurnal Ilmu Farmasi dan Farmasi Klinik},
	journal = {Jurnal Ilmu Farmasi dan Farmasi Klinik},
	volume = {20},
	unique-id = {34471844},
	issn = {1693-7899},
	abstract = {Liraglutide adalah sebuah obat peptida yang digunakan untuk menangani diabetes tipe 2 dan obesitas. Liraglutide diberikan secara injeksi subkutan setiap harinya. Rute injeksi subkutan dapat menyebabkan rasa sakit dan ketidaknyamanan bagi beberapa pasien. Oleh sebab itu, penting untuk meninjau keefektifan dan keamanan rute alternatif ini untuk memastikan bahwa pasien memiliki akses ke pilihan pengobatan yang paling tepat dan nyaman. Rute pemberian alternatif seperti oral dan subkutan yang diperlama pelepasan obatnya, serta topikal, mulai dikembangkan. Artikel review deskriptif ini dibuat dengan metode penelaahan pustaka menggunakan kriteria inklusi dan eksklusi. Beberapa penelitian telah dilakukan untuk mengevaluasi efikasi dan keamanan liraglutide yang diberikan melalui rute alternatif seperti oral dan topikal. Liraglutide yang diberikan melalui rute oral menggunakan teknologi enkapsulasi telah menunjukkan manfaat yang serupa dengan liraglutide yang diberikan melalui injeksi subkutan, ditandai dengan adanya penurunan kadar glukosa darah serta penurunan berat badan yang sebanding. Pemberian liraglutide yang telah dienkapsulasikan melalui injeksi subkutan juga telah diketahui dapat memberikan durasi efek farmakologis yang lebih panjang, sehingga meminimalkan frekuensi pemakaian liraglutide.},
	year = {2023},
	eissn = {2716-3814},
	pages = {75}
}

@article{MTMT:34028665,
	title = {Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport},
	url = {https://m2.mtmt.hu/api/publication/34028665},
	author = {Lenders, Vincent and Koutsoumpou, Xanthippi and Phan, Philana and Soenen, Stefaan J. and Allegaert, Karel and de Vleeschouwer, Steven and Toelen, Jaan and Zhao, Zongmin and Manshian, Bella B.},
	doi = {10.1039/D1CS00574J},
	journal-iso = {CHEM SOC REV},
	journal = {CHEMICAL SOCIETY REVIEWS},
	volume = {52},
	unique-id = {34028665},
	issn = {0306-0012},
	abstract = {This review discusses the strengths and shortcomings of different strategies to facilitate NP transport across barriers of organs and highlights key findings that can stimulate further advances in this field.},
	year = {2023},
	eissn = {1460-4744},
	pages = {4672-4724},
	orcid-numbers = {Lenders, Vincent/0000-0001-9775-3655; Koutsoumpou, Xanthippi/0000-0001-5214-4303; Soenen, Stefaan J./0000-0003-2390-3133; Manshian, Bella B./0000-0002-3402-3927}
}

@article{MTMT:34070225,
	title = {Recent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides},
	url = {https://m2.mtmt.hu/api/publication/34070225},
	author = {Sahandi, Zangabad P. and Abousalman, Rezvani Z. and Tong, Z. and Esser, L. and Vasani, R.B. and Voelcker, N.H.},
	doi = {10.1021/acsabm.3c00193},
	journal-iso = {ACS APPL BIO MATER},
	journal = {ACS APPLIED BIO MATERIALS},
	volume = {6},
	unique-id = {34070225},
	issn = {2576-6422},
	year = {2023},
	pages = {3532-3554}
}

@article{MTMT:34269393,
	title = {Lipid based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application},
	url = {https://m2.mtmt.hu/api/publication/34269393},
	author = {Srivastav, Anurag Kumar and Karpathak, Supriya and Rai, Mohit Kumar and Kumar, Dinesh and Misra, Durga Prasanna and Agarwal, Vikas},
	doi = {10.1016/j.jddst.2023.104526},
	journal-iso = {J DRUG DELIV SCI TEC},
	journal = {JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY},
	volume = {85},
	unique-id = {34269393},
	issn = {1773-2247},
	abstract = {Lipid based drug delivery systems (LBDDS) are valuable and biocompatible nano-carriers for the vehiculation and potential delivery of various hydrophilic, hydrophobic, or amphiphilic compounds. LBDDS have the advantage of targeted drug delivery, as free drugs may have poor targeting, higher systemic toxicity, and pos-sibilities of drug resistance. There is various type of lipid carrier systems for drug delivery based on the properties of drugs and clinical applications; nanoemulsion, microemulsion, lipid vesicles, and lipid nanoparticles. The era of targeted drug delivery is advancing from the superficial convention vesicles to the second generation of LBDDS by modulating the surface chemistry through modifying/surface functionalizing the lipid layer composition. The surfaces of lipid vehicles have been modified with small molecules, antibodies, peptides, and enzymes for tar-geted drug delivery and reduced toxicity. In this regard, polyethylene glycosylation (PEGylation) on the lipid surface was the first novel approach that improves blood circulation time and curtails opsonin resistance and clearance. However, multi-drug and multi-receptor strategies in the targeted-liposomal approach may be an innovative pathway to overcoming drug resistance while treating certain tumors. Several second-generation conventional drug delivery systems among liposomal formulations are at various stages of clinical trials. This review recapitulates the types of lipid formulations, characterization, and their applications in clinical aspects. Additionally, discuss the strategies for enhancement of disease targeting by surface functionalization with various entities to improve the drug delivery system.},
	keywords = {IN-VITRO; Liposome; Drug delivery; AMPHOTERICIN-B; CELLULAR UPTAKE; Ex-vivo; lipid vesicle; nanoemulsion; CANCER-CHEMOTHERAPY; dermal delivery; Gastrointestinal mucus; Multivesicular liposomes; NANOEMULSIFYING OILY FORMULATIONS},
	year = {2023},
	eissn = {2588-8943},
	orcid-numbers = {Kumar, Dinesh/0000-0001-8079-6739}
}

@article{MTMT:34104264,
	title = {The alleviating effect and mechanism of GLP-1 on ulcerative colitis},
	url = {https://m2.mtmt.hu/api/publication/34104264},
	author = {Wang, Wenrui and Zhang, Chuan and Zhang, Haolong and Li, Luyao and Fan, Tingting and Jin, Zhenjing},
	doi = {10.18632/aging.204953},
	journal-iso = {AGING-US},
	journal = {AGING-US},
	unique-id = {34104264},
	issn = {1945-4589},
	year = {2023},
	eissn = {1945-4589}
}

@article{MTMT:33585012,
	title = {Egg Microneedle for Transdermal Delivery of Active Liraglutide},
	url = {https://m2.mtmt.hu/api/publication/33585012},
	author = {You, Jeongyun and Juhng, Seorin and Song, Jieun and Park, Jihyun and Jang, Mingyu and Kang, Geonwoo and Yang, Huisuk and Min, Hye Su and Shin, Jiwoo and Lee, Seri and Ko, Hyuk Wan and Jung, Hyungil},
	doi = {10.1002/adhm.202202473},
	journal-iso = {ADV HEALTHC MATER},
	journal = {ADVANCED HEALTHCARE MATERIALS},
	unique-id = {33585012},
	issn = {2192-2640},
	year = {2023},
	eissn = {2192-2659},
	pages = {2202473},
	orcid-numbers = {Jung, Hyungil/0000-0002-1946-7300}
}

@article{MTMT:34399044,
	title = {Advances of nanoparticles in transmucosal drug delivery},
	url = {https://m2.mtmt.hu/api/publication/34399044},
	author = {Zhang, Li and Yang, Changwei and Song, Yingxiang and Sheng, Tao and Li, Junyan and Yu, Jicheng and Wu, Xiaohong and Ye, Xiao},
	doi = {10.1007/s12274-023-6188-7},
	journal-iso = {NANO RES},
	journal = {NANO RESEARCH},
	unique-id = {34399044},
	issn = {1998-0124},
	year = {2023},
	eissn = {1998-0000}
}

@article{MTMT:33547049,
	title = {Preparation, characterization and in vitro evaluation of chitosan nanoparticles for the oral delivery of GLP-1 analog liraglutide},
	url = {https://m2.mtmt.hu/api/publication/33547049},
	author = {Ziebarth, Jeferson and Mainardes, Rubiana Mara},
	doi = {10.1007/s10973-022-11909-0},
	journal-iso = {J THERM ANAL CALORIM},
	journal = {JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY},
	volume = {148},
	unique-id = {33547049},
	issn = {1388-6150},
	year = {2023},
	eissn = {1572-8943},
	pages = {2443-2455},
	orcid-numbers = {Ziebarth, Jeferson/0000-0001-6790-4272; Mainardes, Rubiana Mara/0000-0002-4442-2075}
}

@inbook{MTMT:33584317,
	title = {Chapter 3. Optimizing the Current Type 2 Diabetes Antidiabetics with Nanotechnologies: Where Do We Stand?},
	url = {https://m2.mtmt.hu/api/publication/33584317},
	author = {Abderrahmani, Amar and Szunerits, Sabine and Dalle, Stephane and Boukherroub, Rabah},
	booktitle = {Nanotechnology for Diabetes Management},
	doi = {10.1039/9781839165498-00092},
	unique-id = {33584317},
	year = {2022},
	pages = {92-112}
}

@mastersthesis{MTMT:33580448,
	title = {Unravelling the modulation of tight junctions: Molecular mechanisms and permeation enhancement},
	url = {https://m2.mtmt.hu/api/publication/33580448},
	author = {Brunner, J},
	doi = {10.13097/archive-ouverte/unige:161111},
	unique-id = {33580448},
	year = {2022}
}

@mastersthesis{MTMT:32797332,
	title = {Establishment of an intestinal tissue model for pre-clinical screenings},
	url = {https://m2.mtmt.hu/api/publication/32797332},
	author = {Christina, Fey},
	doi = {10.25972/OPUS-24410},
	unique-id = {32797332},
	year = {2022}
}

@article{MTMT:33091992,
	title = {NIOSOMES VERSUS PRONIOSOMES AS PROMISING DRUG DELIVERY SYSTEMS IN TREATMENT OF DIABETES MELLITUS},
	url = {https://m2.mtmt.hu/api/publication/33091992},
	author = {H. TEAIMA, MAHMOUD and I. GEBRIL, MOSTAFA and ALLAH, FATHY I. ABD and EL-NABARAWI, MOHAMED A.},
	doi = {10.22159/ijap.2022v14i5.44039},
	journal-iso = {INT J APP PHARM},
	journal = {INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICS},
	volume = {14},
	unique-id = {33091992},
	abstract = {Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people globally in the last few decades. Conventional antidiabetic dosage forms have a lot of problems that necessitate searching for novel drug delivery systems to overcome these drawbacks. Niosomes and proniosomes have been used to carry a wide variety of antidiabetic drugs achieving controlled and sustained release, which improves patient compliance. This review article describes the fundamental aspects of niosomes and proniosomes, including their structural components, methods of preparation, advantages and drawbacks, characterization, factors affecting niosomes formation along with their application in the treatment of diabetes. It also highlights the participation of other drug delivery systems in the treatment of diabetes done, mainly in the last decade.},
	year = {2022},
	eissn = {0975-7058},
	pages = {32-40},
	orcid-numbers = {H. TEAIMA, MAHMOUD/0000-0002-7565-301X; I. GEBRIL, MOSTAFA/0000-0003-4207-5396; EL-NABARAWI, MOHAMED A./0000-0003-0070-1969}
}

@article{MTMT:32548835,
	title = {Oral Bioavailability Enhancement of Melanin Concentrating Hormone, Development and In Vitro Pharmaceutical Assessment of Novel Delivery Systems},
	url = {https://m2.mtmt.hu/api/publication/32548835},
	author = {Kósa, Dóra and Pető, Ágota and Fenyvesi, Ferenc and Váradi, Judit and Vecsernyés, Miklós and Budai, István and Németh, József and Siposné Fehér, Pálma and Bácskay, Ildikó and Ujhelyi, Zoltán},
	doi = {10.3390/pharmaceutics14010009},
	journal-iso = {PHARMACEUTICS},
	journal = {PHARMACEUTICS},
	volume = {14},
	unique-id = {32548835},
	issn = {1999-4923},
	abstract = {The rapid progress in biotechnology over the past few decades has accelerated the large-scale production of therapeutic peptides and proteins, making them available in medical practice. However, injections are the most common method of administration; these procedures might lead to inconvenience. Non-invasive medications, such as oral administration of bio-compounds, can reduce or eliminate pain and increase safety. The aim of this project was to develop and characterize novel melanin concentrating hormone (MCH) formulations for oral administration. As a drug delivery system, penetration enhancer combined alginate beads were formulated and characterized. The combination of alginate carriers with amphiphilic surfactants has not been described yet. Due to biosafety having high priority in the case of novel pharmaceutical formulations, the biocompatibility of selected auxiliary materials and their combinations was evaluated using different in vitro methods. Excipients were selected according to the performed toxicity measurements. Besides the cell viability tests, physical properties and complex bioavailability assessments were performed as well. Our results suggest that alginate beads are able to protect melanin concentrating hormones. It has been also demonstrated that penetration enhancer combined alginate beads might play a key role in bioavailability improvement. These formulations were found to be promising tools for oral peptide delivery. Applied excipients and the performed delivery systems are safe and highly tolerable; thus, they can improve patients’ experience and promote adherence. © 2021 by the authorsLicensee MDPI, Basel, Switzerland.},
	keywords = {Caco-2 Cells; BIOAVAILABILITY; ALGINATE BEADS; penetration enhancers; MTT test; Biocompatibility investigation; Peptide carriers},
	year = {2022},
	eissn = {1999-4923},
	pages = {1-15},
	orcid-numbers = {Budai, István/0000-0002-8966-3817; Ujhelyi, Zoltán/0000-0001-9724-0614}
}

@article{MTMT:33077666,
	title = {Success in Navigating Hurdles to Oral Delivery of a Bioactive Peptide Complement Antagonist through Use of Nanoparticles to Increase Bioavailability and In Vivo Efficacy},
	url = {https://m2.mtmt.hu/api/publication/33077666},
	author = {Xu, Weizhi and Kumar, Vinod and Cui, Cedric S. and Li, Xaria X. and Whittaker, Andrew K. and Xu, Zhi Ping and Smith, Maree T. and Woodruff, Trent M. and Han, Felicity Y},
	doi = {10.1002/adtp.202200109},
	journal-iso = {ADV THER},
	journal = {ADVANCED THERAPEUTICS},
	unique-id = {33077666},
	year = {2022},
	eissn = {2366-3987},
	pages = {2200109},
	orcid-numbers = {Han, Felicity Y/0000-0001-7260-5832}
}

@article{MTMT:32032508,
	title = {A comparison study of Lipid and Polymeric Nanoparticles in the Nasal Delivery of Meloxicam: Formulation, Characterization, and In Vitro Evaluation},
	url = {https://m2.mtmt.hu/api/publication/32032508},
	author = {Akel, Hussein and Ismail, Ruba and Katona, Gábor and Sabir, Fakhara and Ambrus, Rita and Pannonhalminé Csóka, Ildikó},
	doi = {10.1016/j.ijpharm.2021.120724},
	journal-iso = {INT J PHARM},
	journal = {INTERNATIONAL JOURNAL OF PHARMACEUTICS},
	volume = {604},
	unique-id = {32032508},
	issn = {0378-5173},
	year = {2021},
	eissn = {1873-3476},
	orcid-numbers = {Ismail, Ruba/0000-0002-5122-9513; Katona, Gábor/0000-0003-1564-4813; Pannonhalminé Csóka, Ildikó/0000-0003-0807-2781}
}

@article{MTMT:32167160,
	title = {Formulation and In Vitro Comparison Study between Lipid-Based and Polymeric-Based Nanoparticles for Nose-to-Brain Delivery of a Model Drug for Alzheimer’s Disease},
	url = {https://m2.mtmt.hu/api/publication/32167160},
	author = {Akel, Hussein and Pannonhalminé Csóka, Ildikó},
	doi = {10.3390/IECP2020-08680},
	journal-iso = {PROCEEDINGS},
	journal = {PROCEEDINGS},
	volume = {78},
	unique-id = {32167160},
	year = {2021},
	eissn = {2504-3900},
	orcid-numbers = {Pannonhalminé Csóka, Ildikó/0000-0003-0807-2781}
}

@article{MTMT:32531953,
	title = {In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin},
	url = {https://m2.mtmt.hu/api/publication/32531953},
	author = {Akel, Hussein and Pannonhalminé Csóka, Ildikó and Ambrus, Rita and Bocsik, Alexandra and Gróf, Ilona and Mészáros, Mária and Szecskó, Anikó and Kozma, Gábor and Veszelka, Szilvia and Deli, Mária Anna and Kónya, Zoltán and Katona, Gábor},
	doi = {10.3390/ijms222413258},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {22},
	unique-id = {32531953},
	issn = {1661-6596},
	year = {2021},
	eissn = {1422-0067},
	orcid-numbers = {Pannonhalminé Csóka, Ildikó/0000-0003-0807-2781; Kozma, Gábor/0000-0003-2033-0720; Deli, Mária Anna/0000-0001-6084-6524; Kónya, Zoltán/0000-0002-9406-8596; Katona, Gábor/0000-0003-1564-4813}
}

@article{MTMT:31979449,
	title = {Target specific tight junction modulators},
	url = {https://m2.mtmt.hu/api/publication/31979449},
	author = {Brunner, J. and Ragupathy, S. and Borchard, G.},
	doi = {10.1016/j.addr.2021.02.008},
	journal-iso = {ADV DRUG DELIV REV},
	journal = {ADVANCED DRUG DELIVERY REVIEWS},
	volume = {171},
	unique-id = {31979449},
	issn = {0169-409X},
	abstract = {Intercellular tight junctions represent a formidable barrier against paracellular drug absorption at epithelia (e.g., nasal, intestinal) and the endothelium (e.g., blood–brain barrier). In order to enhance paracellular transport of drugs and increase their bioavailability and organ deposition, active excipients modulating tight junctions have been applied. First-generation of permeation enhancers (PEs) acted by unspecific interactions, while recently developed PEs address specific physiological mechanisms. Such target specific tight junction modulators (TJMs) have the advantage of a defined specific mechanism of action. To date, merely a few of these novel active excipients has entered into clinical trials, as their lack in safety and efficiency in vivo often impedes their commercialisation. A stronger focus on the development of such active excipients would result in an economic and therapeutic improvement of current and future drugs. © 2021 The Author(s)},
	keywords = {BIOCHEMISTRY; drug absorption; Mechanism of action; Tight Junctions; Claudin; occludin; Commercialisation; physiological mechanisms; Zonula occludens; permeation enhancers; Paracellular transport; epithelial permeability; Paracellular pathway; Safety and efficiencies; Intercellular tight junctions},
	year = {2021},
	eissn = {1872-8294},
	pages = {266-288}
}

@article{MTMT:32000113,
	title = {Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs},
	url = {https://m2.mtmt.hu/api/publication/32000113},
	author = {Eissa, N.G. and Elsabahy, M. and Allam, A.},
	doi = {10.1016/j.ijpharm.2021.120317},
	journal-iso = {INT J PHARM},
	journal = {INTERNATIONAL JOURNAL OF PHARMACEUTICS},
	volume = {597},
	unique-id = {32000113},
	issn = {0378-5173},
	abstract = {Glucagon-like peptide-1 (GLP-1) receptor agonists are being increasingly exploited in clinical practice for management of type 2 diabetes mellitus due to their ability to lower blood glucose levels and reduce off-target effects of current therapeutics. Nanomaterials had viewed myriad breakthroughs in protecting peptides against degradation and carrying therapeutics to targeted sites for maximizing their pharmacological activity and overcoming limitations associated with their application. This review highlights the latest advances in designing smart multifunctional nanoconstructs and engineering targeted and stimuli-responsive nanoassemblies for delivery of GLP-1 receptor agonists. Furthermore, advanced nanoconstructs of sophisticated supramolecular assembly yet efficient delivery of GLP-1/GLP-1 analogs, nanodevices that mediate intrinsic GLP-1 secretion per se, and nanomaterials with capabilities to load additional moieties for synergistic antidiabetic effects, are demonstrated. © 2021 Elsevier B.V.},
	keywords = {Diabetes; nanomaterials; GLP-1 receptor agonists; GLP-1; Targeted nanostructures},
	year = {2021},
	eissn = {1873-3476}
}

@article{MTMT:32247293,
	title = {Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy},
	url = {https://m2.mtmt.hu/api/publication/32247293},
	author = {Kim, Hyosuk and Jang, Hochung and Cho, Haeun and Choi, Jiwon and Hwang, Kwang Yeon and Choi, Yeonho and Kim, Sun Hwa and Yang, Yoosoo},
	doi = {10.3390/cancers13174435},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {13},
	unique-id = {32247293},
	year = {2021},
	eissn = {2072-6694},
	orcid-numbers = {Kim, Hyosuk/0000-0003-3239-3147}
}

@article{MTMT:32167158,
	title = {An Overview of the Recent Developments and Patents in the Field of Pharmaceutical Nanotechnology},
	url = {https://m2.mtmt.hu/api/publication/32167158},
	author = {Purohit, Deepika and Manchanda, Deeksha and Makhija, Manish and Rathi, Jyoti and Verma, Ravinder and Kaushik, Deepak and Pandey, Parijat},
	doi = {10.2174/1872210514666200909154409},
	journal-iso = {RECENT PAT NANOTECH},
	journal = {RECENT PATENTS ON NANOTECHNOLOGY},
	volume = {15},
	unique-id = {32167158},
	issn = {1872-2105},
	year = {2021},
	eissn = {2212-4020},
	pages = {15-34}
}

@CONFERENCE{MTMT:33634513,
	title = {Potential of polymeric and Lipid based nanocarriers for oral GLP-1 analogue delivery},
	url = {https://m2.mtmt.hu/api/publication/33634513},
	author = {Ismail, Ruba and Pannonhalminé Csóka, Ildikó},
	booktitle = {II. Symposium of Young Researchers on Pharmaceutical Technology, Biotechnology and Regulatory Science},
	doi = {10.14232/syrptbrs.2020.op9},
	unique-id = {33634513},
	year = {2020},
	pages = {14-14},
	orcid-numbers = {Ismail, Ruba/0000-0002-5122-9513; Pannonhalminé Csóka, Ildikó/0000-0003-0807-2781}
}

@article{MTMT:31501141,
	title = {Development of a Biocompatible PLGA Polymers Capable to Release Thrombolytic Enzyme Prourokinase},
	url = {https://m2.mtmt.hu/api/publication/31501141},
	author = {Kaplan, Mikhail A. and Sergienko, Konstantin V and Kolmakova, Anastasia A. and Konushkin, Sergey V and Baikin, Alexander S. and Kolmakov, Alexey G. and Sevostyanov, Mikhail A. and Kulikov, Alexander V and Ivanov, Vladimir E. and Belosludtsev, Konstantin N. and Antipov, Sergey S. and Volkov, Mikhail Yu and Shusharina, Natalya N. and Karaduleva, Elena V and Kozlov, Valery A. and Simakin, Alexander V and Gudkov, Sergey V},
	doi = {10.1080/09205063.2020.1760699},
	journal-iso = {J BIOMAT SCI-POLYM E},
	journal = {JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION},
	volume = {31},
	unique-id = {31501141},
	issn = {0920-5063},
	abstract = {The novelty of the work lies in the creation and study of the physical and biological properties of biodegradable polymer coatings for stents based on poly(lactic-co-glycolic acid) (PLGA). Polymer coatings are capable of prolonged and directed release of molecules with a high molecular weight, in particular, protein molecules of prourokinase (m.w. 54 kDa). A technology has been developed to create coatings having a relative elongation of 40% to 165% and a tensile strength of 25-65 MPa. Coatings are biodegradable; the rate of degradation of the polymer in an isotonic solution varies in the range of 0.05%-1.0% per day. The created coatings are capable of controlled release of the protein of prourokinase, while about 90% of the molecules of prourokinase retain their enzymatic activity. The rate of release of prourokinase can vary from 0.01 to 0.08 mg/day/cm(2). Coatings do not have a short-term toxic effect on mammalian cells. The mitotic index of cells growing on coatings is approximately 1.5%. When implanting the developed polymers in animals in the postoperative period, there are no complications. Histological examination did not reveal pathological processes. When implanting individual polymers 60 days after surgery, only traces of PLGA are detected. Thus, a biodegradable composite mechanically resistant polymer capable of prolonged release of the high molecular weight prourokinase enzyme has been developed.},
	keywords = {COATINGS; controlled release; biocompatibility; prourokinase; PGLa; thrombolytic effect},
	year = {2020},
	eissn = {1568-5624},
	pages = {1405-1420}
}

@article{MTMT:32005188,
	title = {Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds},
	url = {https://m2.mtmt.hu/api/publication/32005188},
	author = {Nie, Xin and Chen, Zhejie and Pang, Lan and Wang, Lin and Jiang, Huajuan and Chen, Yi and Zhang, Zhen and Fu, Chaomei and Ren, Bo and Zhang, Jinming},
	doi = {10.2147/IJN.S285134},
	journal-iso = {INT J NANOMED},
	journal = {INTERNATIONAL JOURNAL OF NANOMEDICINE},
	volume = {15},
	unique-id = {32005188},
	issn = {1176-9114},
	year = {2020},
	eissn = {1178-2013},
	pages = {10215-10240}
}

@article{MTMT:32005186,
	title = {Type II diabetes mellitus: a review on recent drug based therapeutics},
	url = {https://m2.mtmt.hu/api/publication/32005186},
	author = {Padhi, Santwana and Nayak, Amit Kumar and Behera, Anindita},
	doi = {10.1016/j.biopha.2020.110708},
	journal-iso = {BIOMED PHARMACOTHER},
	journal = {BIOMEDICINE & PHARMACOTHERAPY},
	volume = {131},
	unique-id = {32005186},
	issn = {0753-3322},
	year = {2020},
	eissn = {1950-6007},
	orcid-numbers = {Behera, Anindita/0000-0002-2990-0956}
}

@article{MTMT:31320069,
	title = {Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery},
	url = {https://m2.mtmt.hu/api/publication/31320069},
	author = {Ismail, Ruba and Thi, Nhu Quynh Phan and Flavia, Laffleur and Pannonhalminé Csóka, Ildikó and Andreas, Bernkop Schnurch},
	doi = {10.1016/j.ejpb.2020.04.025},
	journal-iso = {EUR J PHARM BIOPHARM},
	journal = {EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS},
	volume = {152},
	unique-id = {31320069},
	issn = {0939-6411},
	year = {2020},
	eissn = {1873-3441},
	pages = {10-17},
	orcid-numbers = {Ismail, Ruba/0000-0002-5122-9513; Pannonhalminé Csóka, Ildikó/0000-0003-0807-2781}
}